Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NHS2eHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIrRWlJEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO MUexPFc2OzVy
A-549 MkDJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3oT2xIS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hSS13NEmgcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1zLkKwSU0xPiEQvF2= M4XSR|E5PzV|NUC=
MCF-7 NVKwclBQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;xcYU4S3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hVUOILUegZpJm[XO2IHPhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuPFBGNTB4IN88US=> MVmxPFc2OzVy
HT-29 MkfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDIWE0zQSClb3zvckBi\GWwb3PhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUGuNlBGNTB4IN88US=> MWSxPFc2OzVy
MLM melanoma cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{niOGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= M3:3WFE5PzV|NUC=
M14 MVHDfZRwfG:6aXPpeJkh[XO|YYm= M4TEdWlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB4[XNidHXzeIVlKGGpYXnud5QhcHWvYX6gcYVt[W6xbXGgZ4Fv[2W{IDjNNVQqKGOnbHygcIlv\SxiR1m1NF0xNjByMEGg{txO Mle1NVI4Ojl4NEC=
SK-OV3 MkLDR5l1d3SxeHnjbZR6KGG|c3H5 M1u5WGlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB1\XO2ZXSgZYdicW6|dDDoeY1idiCxdnHybYFvKGOjbnPldkApW0tvT2[zLUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> MXGxNlczQTZ2MB?=
HL60 cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= MWe3NkBp NHToSG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODBzIN88US=> MVyyNFc{OTN3NR?=
SK-OV-3 NY\XeG55T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjh[XE1QCCq NIHzZ2xIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFAyOyEQvF2= MlPUNVg4OjJzMke=
HepG2 cells MWHDfZRwfG:6aXPpeJkh[XO|YYm= M4PnR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCLQ{WwQVAvODByMUSg{txO NYXNWI5ROTdzMkewOlE>
ZR-75-1 NXLjR2w1S3m2b4TvfIlkcXS7IHHzd4F6 M{nuUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFqULUe1MVEh[2WubDDsbY5mNCCLQ{WwQVAvODByMkSg{txO MXixO|I1QTZ2OR?=
HeLa cell Mof2R5l1d3SxeHnjbZR6KGG|c3H5 MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBJ\UyjIHPlcIwhdGmwZTygTWM2OD1yLkCwNFMh|ryP NG\BR2MyPzJ2OU[0PS=>
HCT116 cell MW\DfZRwfG:6aXPpeJkh[XO|YYm= MnzSR5l1d3SxeHnjbZR6KGGpYXnud5QhUEOWMUG2JINmdGxibHnu[UwhUUN3ME2wMlAxODN3IN88US=> NVvSUmg1OTd{NEm2OFk>
KBV1 cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= MmixO|IhcA>? NFXXV3BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB3cW6kbHHzeIlv\S2{ZYPpd5RidnRiS1LWNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOEDPxE1? M3\ib|IxPzNzM{W1
SKOV3 NYjlV45vS3m2b4TvfIlkcXS7IHHzd4F6 NGT1fJVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= MXGyOFAyPjByMh?=
SKOV3 cells MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVfwR|h1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMESyJO69VQ>? NH3MfogzOzd5MkOwPS=>
HeLa cells NYPHcFdQS3m2b4TvfIlkcXS7IHHzd4F6 M2fVTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVEh|ryP M3ztUVE6QDd7N{W4
DU145 cells MnXmR5l1d3SxeHnjbZR6KGG|c3H5 NGDmXHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA2PCEQvF2= MljTNlQxOTZyMEK=
DU145 cells MkT6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk\2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODV2IN88US=> MljYNlM4PzJ|MEm=
SK-N-BE MVXQdo9tcW[ncnH0bY9vKGG|c3H5 Mlj3O|IhcA>? NWnFRnJLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP M{TkZVIzOzJ7NU[x
NCIH460 cells MX;DfZRwfG:6aXPpeJkh[XO|YYm= MYq0PEBp NUXkUXJRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOkDPxE1? M3\FXVE5OzB|OES5
KB-VIN10 cells NV35N|BVWHKxbHnm[ZJifGmxbjDhd5NigQ>? M374c|czKGh? NHzFO3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP NX;HWYIzOjF4NEG3NFA>
HCT116 cells Mlr3R5l1d3SxeHnjbZR6KGG|c3H5 M{HsTlczKGh? NWnIfXE3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTB;MD6wNFA4PCEQvF2= NF3aSGYzOTl3NUS1OC=>
DU145 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= M1v1[FQ5KGh? MonZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODhizszN M1jBfVE5OzB|OES5
RS4:11 cells NWDLZmk2WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVq3NkBp NVPYR4xzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSV|Q7OTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JEg{NSh2LEWt[Ilu\XSqeXz0bIligm:uLUKtfYwqNTJuNT3kbZBp\W67bITleJJigm:uaYXtJIJzd22rZHWgeIV{fCxiSVO1NF0xNjByMEig{txO MVyyOVc5PTZyNR?=
HCT 116 MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MYSxNVcyPDZzMx?=
HeLa cells MmfaR5l1d3SxeHnjbZR6KGG|c3H5 MYe3NkBp NIfpUW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBz\XOjeoXybY4h[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyPUCuNFAxQSEQvF2= NX7CU4tjOjR4Nkm4PFg>
BNL 1ME A.7R.1 cells NXuxNmduS3m2b4TvfIlkcXS7IHHzd4F6 M1rrPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJPVCBzTVWgRU44Wi5zIHPlcIx{NCCLQ{WwQVAvODByOTFOwG0> NWDWSVhCOjV5OEW2NFU>
Calu6 NXXCPJhxWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnTqOFghcA>? MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIW2JIFnfGW{IES4JIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eTygTWM2OD1yLkCwNFk1KM7:TR?= NV7ncWw{OjF5N{S0PVk>
melanoma B16 cell M3:yRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;XV29Ed26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? NFTkNIwyOTdzNE[xNy=>
DU145 cells M{TSXWN6fG:2b4jpZ4l1gSCjc4PhfS=> NWfYbZp{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= M1K3OVIxPDl4OUKz
HCT116 cells NVvzN2hHWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnzpO|IhcA>? MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M4K3[VIyOTF{MUOw
HCT15 cells NXjNcYFkWHKxbHnm[ZJifGmxbjDhd5NigQ>? MX23NkBp NITKeXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MUOyNVEyOjF|MB?=
HL60 cells NX3meYpOWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWq3NkBp MofURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MYmyNVY3OzNzOR?=
A10 cells MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4fGbVQ5KGh? NXr4NXJNT3Kxd4ToJIlvcGmkaYTpc44hd2ZicnH0JGEyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NYDndlRbOjJyNESxOlQ>
HUVEC cells MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\Qc|Q5KGh? NIXFR5FIem:5dHigbY5pcWKrdHnvckBw\iCKVW\FR{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NHezN4IzOjB2NEG2OC=>
HL60 cells NWfxOYRtS3m2b4TvfIlkcXS7IHHzd4F6 NGjNWYo4OiCq MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NYL3epZvOjJzM{[zNVI>
HL60 cells MVjQdo9tcW[ncnH0bY9vKGG|c3H5 NY\BOotqPzJiaB?= MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M1zyW|IzPTd6MUGx
NCI-H522 cells MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;mOFghcA>? M{D4[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO NXjjOGozOjJ7OEKxNlI>
MDA-MB-435 cells MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17tNlQ5KGh? M2T4cmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M3fyNlIzQTh{MUKy
OVCAR3 MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NELHS2Q1QCCq NIPPe2hIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NHrpbZQzOjl6MkGyNi=>
NCI/ADR-RES cells NILn[HNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1O4clQ5KGh? NFvSenJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MonvNlI6QDJzMkK=
PC3 cells MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX20PEBp NWjLcWQ3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NFnpVlMzOjl6MkGyNi=>
DU145 cells M{S4[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDXOFghcA>? NXi4dHBXT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NHTiSmEzOjl6MkGyNi=>
MDA-MB-231 cells NX\0[mppT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3PjWFQ5KGh? NXXyT3ZWT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MYGyNlk5OjF{Mh?=
CEM cells M1PKemN6fG:2b4jpZ4l1gSCjc4PhfS=> MWq3NkBp NF\ubldEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NXjER3JlOjJ4N{[yOFc>
HCT116 cells MmO5R5l1d3SxeHnjbZR6KGG|c3H5 NIPOV4o4OiCq M1qxWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> M3nhOFIzPjd4MkS3
MDA-MB-435 cells Mm\NR5l1d3SxeHnjbZR6KGG|c3H5 NHHBem04OiCq NGH0fZdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NEjFOHEzOjZ5NkK0Oy=>
HaCaT cells MlTzVJJwdGmoZYLheIlwdiCjc4PhfS=> MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEijQ3HUJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MYWyN|A3OzRyMR?=
HL60 cells M3e3c3Bzd2yrZnXyZZRqd25iYYPzZZk> MkLXO|IhcA>? NV:5SGpySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MUmyN|EyPzF5MR?=
HL60 cells MXzQdo9tcW[ncnH0bY9vKGG|c3H5 NHv4N4s4OiCq MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KCh|LTi0MFUu\GmvZYTofYx1cGmjen;sMVIugWxrLUKsOU1lcXCqZX75cJRmfHKjen;sbZVuKGK{b33p[IUhfGW|dDygTWM2OD1yLkCwNUDPxE1? MXOyOVc5PTZyNR?=
HT-29 M4D6N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWE0zQSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NFn6RZIzPTZ6OUGxNS=>
HL60 cells NWfvd5NJWHKxbHnm[ZJifGmxbjDhd5NigQ>? MoTBO|IhcA>? NYHhOZptSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NUXDWlAxOjB2MkC0N|k>
Hs578T cells MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHv4dGE1QCCq MU\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NYHPelFYOjJ7OEKxNlI>
HL60 cells NVTFNm1nS3m2b4TvfIlkcXS7IHHzd4F6 NIfYS4w4OiCq NVT1S4FUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NFTwSmEzOzR2NUS5Oi=>
SKOV3 cells M3noT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjkNplWT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NEjqWGUzPTZ6OUGxNS=>
MDA-MB-468 cells MnuxR5l1d3SxeHnjbZR6KGG|c3H5 M2fQSlQh\GG7cx?= MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDRiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGxJO69VQ>? M2T3W|I1OjFyNUCz
MCF7 cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 M2\zWlczKGh? MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEyOSEQvF2= NYj0b5lmOjJ|Mkm1OlE>
H460 MkPLR5l1d3SxeHnjbZR6KGG|c3H5 MmC5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKHSnc4SsJGlEPTB;MD6wNFEzKM7:TR?= NXHRSmJqOTh5OEOyNFc>
H460 MYPQdo9tcW[ncnH0bY9vKGG|c3H5 MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh2NkCgZ4VtdHNuIFnDOVA:OC5yMEGyOEDPxE1? M{nMSlE3PzJ{NkOz
NCI-H460 cells NX:1N454S3m2b4TvfIlkcXS7IHHzd4F6 M3z0SVczKGh? MVLDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjD0[ZN1NCCLQ{WwQVAvODBzMzFOwG0> NHjyS|AyQDN7Nki1Oy=>
OVCAR8 cells MlzBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrhSI1qQTZiaB?= NWfmS4p2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK4JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ3z5Z49xem:2ZXnuJIFnfGW{IEm2JIhzeyxiSVO1NF0xNjByMUOg{txO NIiz[o4zOjB2NEG2OC=>
NCI/ADR-RES cells NXvxZZd2S3m2b4TvfIlkcXS7IHHzd4F6 NH34U25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= NGGzOJczOzJzNES1Ni=>
OVCAR8 cells M4PocmN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn3VPVYhcA>? MkTRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP NVnCUVI4OjVyMkW5PVE>
NCI/ADR-RES cells M{TwTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NYTIbWJXQTZiaB?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC5OkBpenNiYomgS4lmdXOjIIP0ZYlvcW6pLXLhd4VlKGyrZ3j0JI1q[3Kxc3PvdJktKEmFNUC9NE4xODF|IN88US=> M{nhR|I2ODJ3OUmx
OVCAR8 cells MlvWR5l1d3SxeHnjbZR6KGG|c3H5 MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyPUCuNFAyOyEQvF2= NF;LbIMzOzJzNES1Ni=>
HuTu 80 cells NGfGTpdRem:uaX\ldoF1cW:wIHHzd4F6 MUS3NkBp M4[w[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJGh2XHViOECgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUO3JO69VQ>? MoTvNlI{Ojl3NkG=
K562 cells M3\aXGN6fG:2b4jpZ4l1gSCjc4PhfS=> NV\FfXhIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjByMUSg{txO NHf1R|UyQTh|N{W5OC=>
NCI/ADR (MDR) cells NEPTcolHfW6ldHnvckBie3OjeR?= MlLoR4VtdCCleXPs[UBienKnc4SgbY4hVkOLL1HEVkApVUSUKTDj[YxteyCkeTDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTygTWM2OD1yLkCwNVUh|ryP NFPWNJEyPjN5N{G4Oy=>
HUVEC MUjQdo9tcW[ncnH0bY9vKGG|c3H5 M2Czb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMtKEmFNUC9NE4xODF3IN88US=> NIfEXpoyPjd{Mk[zNy=>
KB cell NHy5bVRRem:uaX\ldoF1cW:wIHHzd4F6 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= M3jncFE4ODN2MUS3
KB-VIN10 cell MVrQdo9tcW[ncnH0bY9vKGG|c3H5 NXG4eIl2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= NXTLN|dMOTdyM{SxOFc>
Human SH-SY5Y neuroblastoma cells M4TDO2Z2dmO2aX;uJIF{e2G7 M2XIXWlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IFj1cYFvKFOKLWPZOXkhdmW3cn;icIF{fG:vYTDj[YxteyxiSVO1NF0xNjByMUWg{txO M3nsPVE2QTZ|N{Ky
SW620 cells NF;yPYpRem:uaX\ldoF1cW:wIHHzd4F6 MlvXO|IhcA>? M4T5NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNYPjJyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF3MjFOwG0> MkWwNlI{Ojl3NkG=
Molt4/C8 cells MkXlVJJwdGmoZYLheIlwdiCjc4PhfS=> NYHaTlJQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNc4x1PC:FODDj[YxteyxiSVO1NF0xNjByMU[g{txO MlHxNVcxOzRzNUC=
ACHN cell MnznVJJwdGmoZYLheIlwdiCjc4PhfS=> M1z4bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> MY[xO|I5PjN7Mx?=
Molt4/C8 cells MVrQdo9tcW[ncnH0bY9vKGG|c3H5 MX:zJIRigXN? NIPKcYlCdnSrcILvcIln\XKjdHn2[UBm\m[nY4SgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC5yMEG2JO69VQ>? NV6yVHBYOTd2MUm2NFc>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395434 Completed Tumors Mateon Therapeutics September 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID